What is Odomzo (Sonidegib)? A Guide to This Targeted Cancer Medication
•
3 min read
In clinical trials for locally advanced basal cell carcinoma (laBCC), the targeted therapy Odomzo (sonidegib) demonstrated an objective response rate of 56% for patients receiving the 200 mg daily dose. Approved by the FDA, **what is Odomzo** and how does this medication work to treat certain types of skin cancer?
